Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 6: 1177 - 1186

DOI: https://doi.org/10.19852/j.cnki.jtcm.2024.06.006

Research Articles

Weichang’ an pill (胃肠安丸) alleviates functional dyspepsia through modulating brain-gut peptides and gut microbiota

  • Mengting LIAO ,
  • Tao LI ,
  • Fuhao CHU ,
  • Yan CHEN ,
  • Ni LOU ,
  • Yuan ZHUANG ,
  • Rongqiang BO ,
  • Xia DING
Expand
  • 1 Department of Internal Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100010, China
    2 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100010, China
    3 Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100010, China

Received date: 2024-02-18

  Accepted date: 2024-08-21

  Online published: 2024-11-12

Supported by

Horizontal Development Foundation of Beijing University of Chinese Medicine: Research and development of Weicang’an pill in the treatment of functional dyspepsia(2018110031010092)

Fold

Abstract

OBJECTIVE: To evaluate the effect of Weichang’an pill (胃肠安丸, WCAP) on functional dyspepsia (FD) and explore its regulation of brain-gut peptides (BGPs) and gut microbiota balance as a potential treatment mechanism.

METHODS: The "0 ℃ saline gavage + irregular feeding and tail clamp" method was used to establish the FD rat model, excluding the normal group. The successfully established FD rat models were randomly divided into the model group and the WCAP1 (WC1), WCAP2 (WC2), WCAP3 (WC3), WCAP4 (WC4), WCAP5 (WC5), and Domperidone (Dom) groups (n = 10 per group). The unhandled rats were designated as the control group. The gastrointestinal motility of the rats was evaluated using the charcoal propulsion test. Histopathology was assessed by hematoxylin and eosin (HE) staining. The enzyme-linked immunosorbnent assay method was used to detect the levels of motilin (MTL), gastrin (GAS), vasoactive intestinal peptide (VIP), and somatostatin (SS) in the serum from each group. In addition, the gut microbiota composition of fecal samples was analyzed using 16S rRNA sequencing.

RESULTS: Rat models were successfully established according to data from rat state, gastrointestinal motility assessments, and HE staining. WCAP improved FD symptoms by accelerating the gastric emptying and small intestinal transit of FD rats. Mechanistically, WCAP increased the levels of GAS and MTL and reduced the levels of VIP and SS. Moreover, WCAP treatment restored the total relative abundance of Firmicutes and Bacteroidetes, increased the species richness of the gut flora, and modulated the changes in the composition and function of the gut microbiota.

CONCLUSION: WCAP can effectively promote the recovery of gastrointestinal motility disorders in FD rats. The mechanism may be related to regulating the secretion of BGPs and the composition of the gut microbiota.

Key words： gastrointestinal microbiome; functional dyspepsia; brain-gut peptides; Weichang’an pill

Cite this article

Mengting LIAO , Tao LI , Fuhao CHU , Yan CHEN , Ni LOU , Yuan ZHUANG , Rongqiang BO , Xia DING . Weichang’ an pill (胃肠安丸) alleviates functional dyspepsia through modulating brain-gut peptides and gut microbiota[J]. Journal of Traditional Chinese Medicine, 2024 , 44(6) : 1177 -1186 . DOI: 10.19852/j.cnki.jtcm.2024.06.006

References

1. Gabbard S, Vijayvargiya N. Functional dyspepsia: how to manage the burn and the bloat. Cleve Clin J Med 2024; 91: 301-7.
2. Miwa H, Nagahara A, Asakawa A, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol 2022; 57: 47-61.
3. Mounsey A, Barzin A, Rietz A. Functional dyspepsia: evaluation and management. Am Fam Physician 2020; 101: 84-8.
4. Sayuk GS, Gyawali CP. Functional dyspepsia: diagnostic and therapeutic approaches. Drugs 2020; 80: 1319-36.
5. Labanski A, Langhorst J, Engler H, Elsenbruch S. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: a transdisciplinary challenge. Psychoneuroendocrinology 2020; 111: 104501.
6. Rupp SK, Stengel A. Bi-directionality of the microbiota-gut-brain axis in patients with functional dyspepsia: relevance of psychotherapy and probiotics. Front Neurosci 2022; 16: 844564.
7. Tziatzios G, Gkolfakis P, Papanikolaou IS, et al. Gut microbiota dysbiosis in functional dyspepsia. Microorganisms 2020; 8: 691.
8. Karakan T, Ozkul C, Küpeli Akkol E, et al. Gut-brain-microbiota axis: antibiotics and functional gastrointestinal disorders. Nutrients 2021; 13: 389.
9. Mayer EA, Nance K, Chen S. The Gut-brain axis. Annu Rev Med 2022; 73: 439-53.
10. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet 2020; 396: 1689-702.
11. Ho L, Zhong CC, Wong CH, et al. Herbal medicine for functional dyspepsia: network Meta-analysis of placebo-controlled randomised trials. J Ethnopharmacol 2022; 283: 114665.
12. Luo XY, Wang L, Fang SS, et al. Chinese herbal medicine for functional dyspepsia with psychological disorders: a systematic review and Meta-analysis. Front Neurosci 2022; 16: 933290.
13. Wang JB, Zhang LS, Niu BH, et al. Efficacy and safety of Weichang’ an pill combined with Western Medicine on gastrointestinal diseases: a systematic review and Meta-analysis. J Tradit Chin Med 2023; 43: 1057-67.
14. Chen Y, Chu F, Lin J, et al. The mechanisms of action of Weichang’an pill (WCAP) treat diarrhoea-predominant irritable bowel syndrome (IBS-D) using network pharmacology approach and in vivo studies. J Ethnopharmacol 2021; 275: 114119.
15. Zhang GS, Xie S, Hu W, et al. Effects of electroacupuncture on interstitial cells of cajal (ICC) ultrastructure and connexin 43 protein expression in the gastrointestinal tract of functional dyspepsia (FD) rats. Med Sci Monit 2016; 22: 2021-27.
16. Pan XL, Zhou L, Wang D, et al. Electroacupuncture at Zusanli (ST36) promotes gastrointestinal motility possibly by suppres-sing excessive autophagy via AMPK/ULK1 signaling in rats with functional dyspepsia. Zhen Ci Yan Jiu 2019; 44: 486-91.
17. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference from illumina amplicon data. Nat Methods 2016; 13: 581-3.
18. Bokulich NA, Kaehler BD, Rideout JR, et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome 2018; 6: 90.
19. Rohart F, Gautier B, Singh A, Lê Cao KA. mixOmics: an R package for’omics feature selection and multiple data integration. PLoS Comput Biol 2017; 13: e1005752.
20. Oshima T. Functional dyspepsia: current understanding and future perspective. Digestion 2024; 105: 26-33.
21. Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 187-94.
22. Agirman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis. Science 2021; 374: 1087-92.
23. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012; 10: 735-42.
24. Schubert ML, Rehfeld JF. Gastric peptides-gastrin and somatostatin. Compr Physiol 2019; 10: 197-228.
25. Zhang Q, Li G, Zhao W, et al. Efficacy of bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial. Nat Commun 2024; 15: 227.
26. Mori H, Verbeure W, Tanemoto R, Sosoranga ER, Jan Tack. Physiological functions and potential clinical applications of motilin. Peptides 2023; 160: 170905.
27. Kitazawa T, Kaiya H. Motilin comparative study: structure, distribution, receptors, and gastrointestinal motility. Front Endocrinol 2021; 12: 700884.
28. Scirocco A, Pallotta L, Rengo M, et al. Myogenic oxidative imbalance interferes with antral motility in obese subjects. Dig Liver Dis 2018; 50: 820-7.
29. Conlin VS, Wu X, Nguyen C, et al. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol 2009; 297: 735-50.
30. Van den Houte K, Scarpellini E, Verbeure W, et al. The role of GI peptides in functional dyspepsia and gastroparesis: a systematic review. Front Psychiatry 2020; 11: 172.
31. Shen XY, Xie AJ, Li ZQ, et al. Research progress for probiotics regulating intestinal flora to improve functional dyspepsia: a review. Foods 2024; 13: 151.
32. Fujisaka S, Watanabe Y, Tobe K. The gut microbiome: a core regulator of metabolism. J Endocrinol 2023; 256: e220111.
33. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 2022; 28: 4053-60.
34. Wahlstr?m A, Sayin S I, Marschall H-U, B?ckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016; 24: 41-50.
35. Li ZY, Zhang RR, Mu HN, et al. Oral administration of branched-chain amino acids attenuates atherosclerosis by inhibiting the inflammatory response and regulating the gut microbiota in apoe-deficient mice. Nutrients 2022; 14: 5065.
36. Kraimi N, Ross T, Pujo J, De Palma G. The gut microbiome in disorders of gut-brain interaction. Gut Microbes 2024; 16: 2360233.
Options
Outlines

/

〈 〉